Home New England Boston, MA Rapport Therapeutics COMPANY
Clinical Phase 3
18 open jobs · last seen Oct 23, 2026 · 6 sources
Keywords: neurology Focal Seizure Epilepsy Focal Epilepsy Bipolar 1 Disorder Focal Onset Seizures Refractory Focal Epilepsy Seizure Focal Onset Seizure RAP-219 Show all 10 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Senior Director, Global Patient Safety Science Boston, MA Oct 22, 2026 Oct 23, 2026 Sr. Clinical Trial Associate Boston, MA Oct 13, 2026 Oct 14, 2026 Senior Manager, Trial Awareness & Recruitment Boston, MA Oct 5, 2026 Oct 8, 2026 Director, Clinical Contracts Boston, MA Sep 22, 2026 Oct 8, 2026 Associate Director/Director, Regulatory Strategy Boston, MA Aug 12, 2026 Oct 8, 2026
See all 18 jobs
At a glance HQ Boston, MA source Region New England Stage Clinical Phase 3 Latest trial Phase 3: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures (2026-09) source Timeline Oct 8, 2026 Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗ 2026-09 Trial start Phase 3: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures source ↗ Jun 5, 2026 Trial start Phase 3: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 source ↗ Dec 15, 2025 Trial start Phase 2: A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures source ↗ Jul 25, 2025 Trial start Phase 2: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder source ↗ Oct 10, 2024 Trial start Phase 2: Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy source ↗ Upcoming milestones Feb 3, 2028 (ESTIMATED) · Phase 2 · A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · NCT07219407 2029-07 (ESTIMATED) · Phase 3 · Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 · NCT07563881 2029-07 (ESTIMATED) · Phase 3 · Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures · NCT07594119 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 18 Title Location (from posting, not HQ) Employer posted First seen Level Senior Director, Global Patient Safety Science Boston, MA Oct 22, 2026 Oct 23, 2026 Not stated Sr. Clinical Trial Associate Boston, MA Oct 13, 2026 Oct 14, 2026 Senior Description Senior Manager, Trial Awareness & Recruitment Boston, MA Oct 5, 2026 Oct 8, 2026 Senior Description Director, Clinical Contracts Boston, MA Sep 22, 2026 Oct 8, 2026 Senior Description Associate Director/Director, Regulatory Strategy Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description VP, Program Leader Boston, MA Aug 12, 2026 Oct 8, 2026 Executive Description Senior Clinical Trial Manager Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description Sr. Clinical Trial Associate Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description Associate Director, Medical Writing Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description (Senior) Medical Director, Psychiatry Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description Senior Manager/Associate Director, Biostatistics Remote Aug 12, 2026 Oct 8, 2026 Senior Description Senior Manager/Associate Director, Statistical Programming Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description Associate Director, New Product Planning Boston, MA Aug 12, 2026 Oct 8, 2026 Senior Description VP, Business Development Boston, MA Aug 6, 2026 Oct 8, 2026 Executive Description Senior Medical Science Liaison (Central) Remote Jul 6, 2026 Oct 8, 2026 Senior Description Senior Medical Science Liaison (Northeast) Boston, MA Jul 6, 2026 Oct 8, 2026 Senior Description Associate Director, Regulatory Strategy Boston, MA Jun 30, 2026 Oct 8, 2026 Senior Description Director, Clinical Business Operations Boston, MA Jun 25, 2026 Oct 8, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Clinical trials (lead sponsor) 5 Record Title Phase Status Start Primary completion NCT07563881 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 Phase 3 Recruiting Jun 5, 2026 2029-07 (estimated) NCT07594119 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures Phase 3 Recruiting 2026-09 2029-07 (estimated) NCT07046494 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder Phase 2 Active, not recruiting Jul 25, 2025 Aug 5, 2026 (actual) NCT06377930 Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy Phase 2 Completed Oct 10, 2024 Sep 26, 2025 (actual) NCT07219407 A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures Phase 2 Recruiting Dec 15, 2025 Feb 3, 2028 (estimated)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗ Investor Listed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗ Connect See your connections at Rapport Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
